Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 27, 2026
FIGS Stock: Can It Climb to $20? Assessing the +110% Upside Case

FIGS Stock: Can It Climb to $20? Assessing the +110% Upside Case

Key Takeaways

  • Price Target: $20 per share — a level not yet reached in FIGS's current cycle and representing roughly 110% upside from recent prices around $9.50.
  • Strongest Bullish Factors: Accelerating revenue growth (28% in Q1 2026), international expansion gaining traction, active customers surpassing 3 million, and a debt-free balance sheet with $277 million in net cash.
  • Biggest Risks: Tariff pressures on sourcing costs, freight headwinds, margin recovery still in progress, and the stock's elevated valuation even after the recent pullback.
  • Key Technical Levels: The $8–$10 zone serves as a critical support area; a sustained move above the 200-day moving average near $12.79 would signal recovering momentum toward prior resistance near $15–$17.
  • Bottom Line: Reaching $20 is plausible over a multi-year horizon if international expansion and margin recovery accelerate, but the near-term path is challenged by tariff uncertainty and the stock's recent loss of momentum.

Why Investors Are Watching the $20 Level

FIGS, Inc., the direct-to-consumer healthcare apparel company, has experienced a dramatic round-trip over the past year. After trading below $4 in early 2025, the stock staged a powerful recovery, surging above $17 by March 2026 behind strong earnings and a flurry of analyst upgrades. Since that peak, however, shares have retreated sharply, settling near $9.50 as of late July 2026. The question now confronting investors is whether the growth story can regain enough momentum to push the stock toward $20 — a psychologically significant level that would represent new highs for this cycle and align with the most bullish Wall Street targets.

Company Overview

Founded in 2013 by Heather Hasson and Trina Spear, FIGS disrupted the staid medical uniform industry by designing premium scrubs and healthcare apparel with the fit, feel, and branding sensibility of athleisure. The company went public in May 2021 at $22 per share and briefly traded above $50 during the pandemic-era surge in healthcare spending. Today, FIGS generates trailing twelve-month revenue of approximately $666 million, serves over 3 million active customers, and operates across North America, Europe, Asia Pacific, and the Middle East through its e-commerce platform and a growing network of physical retail locations.

What Could Drive the Next Leg Higher

Several catalysts could support a move toward $20. First, international expansion is delivering tangible results — international sales grew approximately 50% year-over-year in the most recent quarter. The company's TEAMS platform, which serves healthcare institutions through bulk purchasing, represents a largely untapped B2B opportunity. Management raised full-year 2026 revenue growth guidance to 14%–16% following Q1 results that delivered $159.9 million in revenue, a 28% increase from the prior year. The company's balance sheet remains a source of strength, with $277 million in net cash and no long-term debt, providing ample flexibility for share buybacks and strategic investments. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Wall Street has taken notice. Oppenheimer carries a $22 price target with an Outperform rating, while BTIG maintains a Buy rating with a $20 target. KeyBanc's Overweight rating and $19 target reflect confidence that the company's "growth algorithm remains intact," citing healthy customer engagement trends and limited resistance to recent pricing actions.

What Could Prevent the Move

Tariffs remain the most significant obstacle. Section 122 tariffs, currently at 10% and potentially rising to 15%, directly pressure gross margins on imported goods. Management acknowledged that freight cost headwinds and the pause of a duty drawback program will create an uneven margin cadence throughout 2026. While Q1 gross margin improved modestly to 67.7%, the full-year outlook assumes only slight improvement over 2025's 66.5%.

Competition also deserves attention. The healthcare apparel market, while historically fragmented, is attracting attention from larger players. Lower-priced alternatives continue to test FIGS's premium positioning, and the company must demonstrate that its brand strength can sustain pricing power without relying on promotions that erode profitability.

Technical Levels That Matter

The stock's technical picture presents a mixed outlook. After peaking at $17.48 in early March 2026, shares have fallen below both the 50-day moving average near $12.69 and the 200-day moving average near $12.79 — a configuration that typically signals bearish momentum. The $9–$10 zone represents an important support area; a breakdown below this range could expose the stock to the mid-$7 area, where Goldman Sachs's prior price target sat before its February upgrade. On the upside, reclaiming the $12–$13 region would be a necessary first step toward rebuilding confidence, with the prior peak near $17 serving as the next major resistance zone before $20 becomes a realistic discussion. From what I see, monitoring these levels closely helps frame the risk-reward picture.

Analyst Opinions and Price Targets

The analyst community holds a Moderate Buy consensus on FIGS, with an average 12-month price target near $15.93, according to MarketBeat data from 11 covering analysts. However, targets span a wide range — from a bearish $7.50 to a bullish $22.00 — reflecting genuine disagreement about the company's trajectory. The clustering of targets between $15 and $20 suggests that even bullish analysts are tempering enthusiasm with caution around margin recovery and valuation. Notably, the average target represents approximately 56% upside from current levels but still falls meaningfully short of $20, underscoring that the $20 objective requires execution beyond the consensus base case.

Valuation Perspective

Even after its recent decline, FIGS trades at a trailing P/E ratio above 40 — a premium multiple that leaves little room for disappointment. The forward P/E near 34 suggests the market expects significant earnings growth to materialize. For the stock to reach $20 without multiple expansion, EPS would need to roughly double from current levels. With FY2026 consensus EPS estimates around $0.25–$0.27 and FY2027 projections near $0.35, reaching $20 would likely require maintaining an elevated growth multiple while delivering consistent earnings beats — a demanding but not impossible combination.

Final Assessment

The path to $20 for FIGS stock is plausible but conditional. The company's revenue growth trajectory, international momentum, fortress balance sheet, and growing customer base provide a credible foundation. However, the near-term reality includes tariff headwinds, margin uncertainty, and a stock that has lost technical momentum. Reaching $20 would likely require multiple catalysts to align: successful mitigation of tariff impacts, sustained margin expansion, accelerating international contribution, and a broader market environment supportive of growth-at-a-reasonable-price narratives. Investors should monitor the upcoming Q2 earnings report in early August 2026 for updated guidance on margins, tariff assumptions, and progress on international initiatives — these will be critical signposts on the road to $20.

Using Tickeron’s AI Daily Buy/Sell Signals in My Process

Navigating a stock with as much volatility as FIGS requires timely, data-driven insight. In my own analysis, I often rely on Tickeron’s AI Daily Buy/Sell Signals to monitor shifting conditions across thousands of stocks and ETFs. The platform’s AI evaluates technical patterns and fundamentals to generate Buy, Sell, or Hold signals, helping me stay ahead of potential trend changes without replacing my own due diligence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: FIGS

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


FIGS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for FIGS turned positive on July 16, 2026. Looking at past instances where FIGS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FIGS's RSI Oscillator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 28, 2026. You may want to consider a long position or call options on FIGS as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FIGS advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

FIGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for FIGS moved below the 200-day moving average on July 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FIGS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FIGS entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FIGS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.359) is normal, around the industry mean (6.327). P/E Ratio (51.091) is within average values for comparable stocks, (29.983). FIGS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.144). FIGS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.023). FIGS's P/S Ratio (3.171) is very high in comparison to the industry average of (0.923).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FIGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are VF Corp (NYSE:VFC), G-III Apparel Group Ltd (NASDAQ:GIII), Canada Goose Holdings (NYSE:GOOS), Lakeland Industries (NASDAQ:LAKE).

Industry description

Apparel/footwear might be slightly more ‘cyclical’ in the largely non-cyclical category of non-durables. While digital giants like Amazon have been rapidly expanding their presence, traditional clothing/footwear retailers have also been bulking up their online presence in recent years, to milk the burgeoning trend of online shopping among consumers across the globe. The apparel and footwear retail market was valued at around $ 360 billion in 2018, and this figure was expected to reach about $386 billion by 2020 (according to a Statista report). NIKE, Inc, V.F. Corporation and Under Armour, Inc. are some of the companies with the largest U.S. stock market caps in this segment.

Market Cap

The average market capitalization across the Apparel/Footwear Industry is 3.29B. The market cap for tickers in the group ranges from 1.66K to 27.62B. HNNMY holds the highest valuation in this group at 27.62B. The lowest valued company is SQBGQ at 1.66K.

High and low price notable news

The average weekly price growth across all stocks in the Apparel/Footwear Industry was -0%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 18%. SGC experienced the highest price growth at 15%, while JXG experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Apparel/Footwear Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 50
Price Growth Rating: 49
SMR Rating: 72
Profit Risk Rating: 90
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
FIGS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ApparelFootwear

Profile
Details
Industry
N/A
Address
2834 Colorado Avenue
Phone
+1 424 300-8330
Employees
354
Web
https://www.wearfigs.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.